Once-daily single-inhaler triple versus dual therapy in patients with COPD DA Lipson, F Barnhart, N Brealey, J Brooks, GJ Criner, NC Day, ... New England Journal of Medicine 378 (18), 1671-1680, 2018 | 1241 | 2018 |
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a … S Pascoe, N Locantore, MT Dransfield, NC Barnes, ID Pavord The lancet Respiratory medicine 3 (6), 435-442, 2015 | 872 | 2015 |
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy HA Ghofrani, NW Morrell, MM Hoeper, H Olschewski, AJ Peacock, ... American journal of respiratory and critical care medicine 182 (9), 1171-1177, 2010 | 477 | 2010 |
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD ID Pavord, S Lettis, N Locantore, S Pascoe, PW Jones, JA Wedzicha, ... Thorax 71 (2), 118-125, 2016 | 420 | 2016 |
FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease DA Lipson, H Barnacle, R Birk, N Brealey, N Locantore, DA Lomas, ... American journal of respiratory and critical care medicine 196 (4), 438-446, 2017 | 387 | 2017 |
Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease DA Lipson, C Crim, GJ Criner, NC Day, MT Dransfield, DMG Halpin, ... American journal of respiratory and critical care medicine 201 (12), 1508-1516, 2020 | 245 | 2020 |
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial S Pascoe, N Barnes, G Brusselle, C Compton, GJ Criner, MT Dransfield, ... The Lancet Respiratory Medicine 7 (9), 745-756, 2019 | 230 | 2019 |
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised … LA Lee, Z Bailes, N Barnes, LP Boulet, D Edwards, A Fowler, NA Hanania, ... The Lancet Respiratory Medicine 9 (1), 69-84, 2021 | 207 | 2021 |
Serious asthma events with fluticasone plus salmeterol versus fluticasone alone DA Stempel, IH Raphiou, KM Kral, AM Yeakey, AH Emmett, CM Prazma, ... New England Journal of Medicine 374 (19), 1822-1830, 2016 | 185 | 2016 |
Blood eosinophil levels as a biomarker in COPD G Brusselle, ID Pavord, S Landis, S Pascoe, S Lettis, N Morjaria, ... Respiratory medicine 138, 21-31, 2018 | 148 | 2018 |
Safety of adding salmeterol to fluticasone propionate in children with asthma DA Stempel, SJ Szefler, S Pedersen, RS Zeiger, AM Yeakey, LA Lee, ... New England Journal of Medicine 375 (9), 840-849, 2016 | 145 | 2016 |
Understanding asthma-chronic obstructive pulmonary disease overlap syndrome KE Wurst, K Kelly-Reif, GA Bushnell, S Pascoe, N Barnes Respiratory medicine 110, 1-11, 2016 | 127 | 2016 |
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol SJ Pascoe, DA Lipson, N Locantore, H Barnacle, N Brealey, R Mohindra, ... European Respiratory Journal 48 (2), 320-330, 2016 | 102 | 2016 |
Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis PW Jones, JF Donohue, J Nedelman, S Pascoe, G Pinault, C Lassen Respiratory research 12, 1-10, 2011 | 82 | 2011 |
Bronchodilator effects of indacaterol and formoterol in patients with COPD J Beier, KM Beeh, L Brookman, G Peachey, A Hmissi, S Pascoe Pulmonary pharmacology & therapeutics 22 (6), 492-496, 2009 | 71 | 2009 |
The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study LA Lee, S Yang, E Kerwin, R Trivedi, LD Edwards, S Pascoe Respiratory medicine 109 (1), 54-62, 2015 | 58 | 2015 |
Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis DR Hinds, RL DiSantostefano, HV Le, S Pascoe BMJ open 6 (6), e010099, 2016 | 56 | 2016 |
A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma LA Lee, A Briggs, LD Edwards, S Yang, S Pascoe Respiratory medicine 109 (1), 63-73, 2015 | 48 | 2015 |
The effect of exacerbation history on outcomes in the IMPACT trial DMG Halpin, MT Dransfield, MLK Han, CE Jones, S Kilbride, P Lange, ... European Respiratory Journal 55 (5), 2020 | 43 | 2020 |
A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with≤ 2% and> 2% blood … J Marks-Konczalik, M Costa, J Robertson, E McKie, S Yang, S Pascoe Respiratory Medicine 109 (7), 860-869, 2015 | 40 | 2015 |